The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology
In early 2016, the FDA and the National Institutes of Health (NIH) published the first version
of the glossary included in the Biomarkers, EndpointS, and other Tools (BEST) resource …
of the glossary included in the Biomarkers, EndpointS, and other Tools (BEST) resource …
Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version …
These joint practice guidelines, or procedure standards, were developed collaboratively by
the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and …
the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and …
Update on amino acid PET of brain tumours
KJ Langen, N Galldiks - Current opinion in neurology, 2018 - journals.lww.com
PET using radiolabelled amino acids is a rapidly evolving method that can significantly
enhance the diagnostic value of MRI in brain tumours. Current developments suggest that …
enhance the diagnostic value of MRI in brain tumours. Current developments suggest that …
Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric 18F-FET PET-MRI and MR Fingerprinting
J Haubold, A Demircioglu, M Gratz, M Glas… - European Journal of …, 2020 - Springer
Objectives The introduction of the 2016 WHO classification of CNS tumors has made the
combined molecular and histopathological characterization of tumors a pivotal part of glioma …
combined molecular and histopathological characterization of tumors a pivotal part of glioma …
Static and dynamic 18F–FET PET for the characterization of gliomas defined by IDH and 1p/19q status
Purpose The molecular features isocitrate dehydrogenase (IDH) mutation and 1p/19q co-
deletion have gained major importance for both glioma typing and prognosis and have …
deletion have gained major importance for both glioma typing and prognosis and have …
Glioma survival prediction with combined analysis of in vivo 11C-MET PET features, ex vivo features, and patient features by supervised machine learning
L Papp, N Pötsch, M Grahovac… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Gliomas are the most common type of tumor in the brain. Although the definite diagnosis is
routinely made ex vivo by histopathologic and molecular examination, diagnostic work-up of …
routinely made ex vivo by histopathologic and molecular examination, diagnostic work-up of …
Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas
Background PET with radiolabeled amino acids is used in the preoperative evaluation of
patients with glial neoplasms. This study aimed to assess the role of [11C] methionine (MET) …
patients with glial neoplasms. This study aimed to assess the role of [11C] methionine (MET) …
Integration of dynamic parameters in the analysis of 18F-FDopa PET imaging improves the prediction of molecular features of gliomas
M Ginet, T Zaragori, PY Marie, V Roch… - European journal of …, 2020 - Springer
Abstract Purpose 18 F-FDopa PET imaging of gliomas is routinely interpreted with
standardized uptake value (SUV)-derived indices. This study aimed to determine the added …
standardized uptake value (SUV)-derived indices. This study aimed to determine the added …
Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic 18F-FET PET
F Vettermann, B Suchorska, M Unterrainer… - European journal of …, 2019 - Springer
Purpose According to the updated WHO classification of gliomas with its emphasis on
molecular parameters, tumours with an IDH-wildtype status have a dismal prognosis. To …
molecular parameters, tumours with an IDH-wildtype status have a dismal prognosis. To …
18F-DOPA PET/CT in brain tumors: impact on multidisciplinary brain tumor board decisions
Purpose This study aimed to assess the therapeutic impact and diagnostic accuracy of 18 F-
DOPA PET/CT in patients with glioblastoma or brain metastases. Methods Patients with …
DOPA PET/CT in patients with glioblastoma or brain metastases. Methods Patients with …